Non-executive Chairman

Don has 30 years’ experience as a senior partner of Ernst & Young, Oceania, has extensive experience in IPO’s, transactions and audit.  Don has advised and worked with Boards of organisations, ranging from some of the largest in Australia to fast growing entrepreneurial and medium sized organisations.

Don was the Oceania IPO Leader at Ernst & Young and worked with clients listing on the Australian, US, UK and key Asian stock exchanges.  He held positions as Biotech Markets Leader, National Leader of Strategic Growth Markets and on the Board of Partners of Ernst & Young.

Don is a Fellow of Chartered Accountants Australia & New Zealand, a member of the Australian Institute of Company Directors and a former Director of Murray River Organics Group Limited.

RICHARD JAGGER (B.Sc.(hons), M.Intl.Bus., GAICD)

Chief Executive Officer and Managing Director

Richard has over 20 years’ experience in the Agricultural sector, working for Fortune 500 companies around the world. He managed the introduction of Australia’s first agricultural biotech products into the cotton sector. Having worked as a senior executive manager for Monsanto within Australia and New Zealand, he has extensive knowledge of the local business and distribution network, as well as the major crop protection companies globally. He co-created the Australian subsidiary of Sinochem – one of the largest Crop Protection companies in China – in the role of Managing Director. He was previously a board member of Crop Life Australia, the peak national industry organisation representing the agricultural chemical and biotechnology (plant science) sector in Australia. Richard is a founding member of Victoria’s Cleantech Cluster, designed to support, consolidate and promote clean, sustainable technology for use around the world.

Richard has extensive experience in business management, continuous improvement, strategy development, culture evolution, and technology and innovation implementation. With the opportunity to work with different cultures and business styles across the globe, he has a solid understanding of what is required to make a success of cross cultural, or cross geographical businesses.


Non-executive Director

Robert is a highly experienced professional uniquely experienced in translating and commercialising early stage intellectual property from a variety of technology areas into commercial product or investable corporate vehicles. He is an Australian registered patent attorney who has had a wide and successful career to date within both private and publicly traded companies as well as the academic arena. He has over 30 year’s corporate experience in the international technology development arena.

He has focused primarily on biotechnology and biotechnology corporate development, particularly healthcare related, but has also been involved in the commercialisation of software, scientific instrumentation, food technologies and enabling agricultural technology. Robert has deep expertise and experience in all facets of corporate development and technology transfer including IP licensing, patenting, intellectual property strategy and management, joint venture creation and management, fund-raising (private and public markets), corporate and scientific due diligence, technology and corporate acquisitions, corporate compliance and corporate governance and academic liaison. He is the founder of 26 companies in Australia and Singapore. He is a highly experienced professional Director having been an Executive or Non-Executive Chairman/Director on over 24 different corporate entities. He was previously a member of the Pharmaceutical Industry Group and is currently a member of the Victorian Biotechnology Advisory Committee.

Robert is scientifically trained in pharmacology and biochemistry and has a deep understanding of molecular biology, genetics, bioinformatics, immunology, ophthalmology (device and therapeutic), neurosciences, oncology, reproductive biology and stem cell biology. He was Managing Director and CEO of ASX listed Circadian Technologies Pvt Ltd from 2008-2013 and in 2017 was appointed CEO of the Bionics Institute.

PETER MAY (BAppSc (Rural Technology) (Hons), MBA, GAICD, AFAIM)

Executive Director Research and Development

Peter has over 20 years’ experience in the Australian and international crop protection markets with companies Incitec, Orica and Crop Care Australasia (now part of Nufarm). His various roles included business management of pesticide products, export sales and toll formulation operations. During this period Peter developed extensive experience in international crop protection markets.

In 2001, he founded Xavca Pty Ltd, providing marketing and consultancy services to companies such as Syngenta, Sorex (now part of BASF), Babolna Bioenvironmental (Hungary) and Proplan Plant Protection (Spain). In 2008 Peter joined BioProspect Limited (ASX: BPO) as Chief Executive Officer and subsequently was appointed Non-Executive Director and then Non-Executive Chairman. In 2012 Peter joined Xenex Associates, a UK-based international consultancy company, as a Senior Associate, working on market development projects in Asia/Oceania.

Peter is a graduate member of the Australian Institute of Company Directors (AICD), a member of the Australian Environmental Pest Managers Association (AEPMA) and the Mosquito Control Association of Australia (MCAA).  Peter holds a Bachelor of Applied Science (Rural Technology) (First Class Honours) from the University of Queensland and an MBA from the Queensland University of Technology.


Non-executive Director

Kevin is a founding director of Bio-Gene Technology Limited. He has had an extensive career in the fields of Advertising and Marketing having run his own Advertising Agency for more than 20 years. He has more than 20 years’ experience in new plant propagation, farming, and processing and live plant transport techniques.

Kevin was instrumental in securing the contract with the University of Western Australia to grow Boronia megastigma and producing essential oil that was regarded as the best of its type in the world and was highly valued. He also secured the contract in Western Australia for exclusive access to that State’s native flora.

He has been involved in the development of Qcide™ from the outset and has a vast knowledge of the plant husbandry and the extraction methods used to produce natural Qcide™. Kevin also initiated the project to develop the synthesis of flavesone as a first step in the commercialisation of Flavocide™.

Kevin has announced that he will retire as a Director at the 2020 AGM.  Click here to review the ASX Announcement.


Chief Financial Officer and Company Secretary

Roger has more than 20 years’ experience in senior finance roles in a wide variety of industries.  His early career included working with a Chartered Accounting practice and two years with the Australian Taxation Office.

Before Bio-Gene, Roger was CFO and Company Secretary for a number of SMEs both listed and unlisted including Patrys Limited, TPI Enterprises Ltd and eChoice Home Loans.  In these roles he was responsible for all financial affairs and corporate administration as well as assisting in investor relations activities.  He has over 15 years of biotechnology and pharmaceutical experience.

He is a CPA and a graduate of the Australian Institute of Company Directors.


Program Manager

James was educated in the UK, obtaining a bachelor’s degree in Biological Science (University of Salford, UK) and a Master’s degree (with distinction) in Molecular Parasitology and Entomology (University of Manchester, UK). This training provided a strong understanding of contemporary studies relating to research into the immunological and molecular aspects of selected parasites and vector/parasite relationships. A specific emphasis was placed on the epidemiology and control of vectors of known economic importance and their impacts on the public, animal and agricultural sectors.

After completing a PhD in cell and developmental biology in 2008, James was employed as a Science and Technology Program Manager for a world leading European-based agribusiness holding company (EW-Group). In this role he was responsible for a global program of collaborative research projects which aimed to improve company process efficiencies.

In 2015 James joined a subsidiary of the EW-Group (Aviagen Ltd) as Research/Technical Development Manager (an EW-Group owned company). Here he assisted in leading a broad range of research initiatives aimed at improving the understanding of Aviagen’s products, processes, and developing best-practice advice for customers. This involved cross cultural and geographical collaborations with private industry, leading academic institutions and government organisations. This role saw James gain further experience in the coordination multiple cross disciplinary research projects in order to develop new technologies and methods that would add value to the Aviagen business. As part of this role he was responsible for the management of company trials infrastructure, the management, analysis and interpretation of product and research and development trials run internally or in external facilities across Europe. This role delivered multiple research outputs and technical support internally to the company, customer and wider audiences.

James was appointed as Program Manager for R&D within Bio-Gene in December 2018.